the major downstream RAS effectors PI3K, RAF and RAL–GEF and cytokine signaling pathways. Examples of clinical-stage small-molecule kinase inhibitors that target each signaling axis are also ...

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function ... for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic ...

Candel Therapeutics (CADL) announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for ...

The MAP kinase family includes the extracellular-signal related kinases (ERKs), which signal through a pathway involving sequential activation of Ras, Raf and mitogen-activated protein kinase ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Immuneering Corp. Class A ( (IMRX) ) has released its Q3 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented ...

In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

NIH researchers found that mutant RAS genes can promote cancer through a novel mechanism, leading to enhanced tumor growth. This discovery suggests new combined drug approaches may be more effective ...

Schematic models of the core of MAPK/ERK pathway and human eIF3 complex. (A) The MAPK/ERK pathway activation by growth factors and receptor tyrosine kinases (RTKs). RTKs signal through GRB2-Sos and ...